Halodine Nasal Antiseptic in Patients With COVID-19
Status:
Not yet recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
Povidone iodine (PVP-I) is a well-known broad spectrum, resistance free antimicrobial agent
that has a long history of safe and effective use. Halodine Nasal Antiseptic is formulated
for topical application PVP-I to nasal passages, and has demonstrated effectiveness against
SARS-COV-2 in vitro - 99.99% inactivation within 15 seconds. This study will evaluate the
ability of Halodine Nasal Antiseptic to impact SARS-CoV-2 in vivo.